Accelerate Diagnostics Inc. (AXDX) Shares Bought by Swiss National Bank
Swiss National Bank increased its position in shares of Accelerate Diagnostics Inc. (NASDAQ:AXDX) by 2.7% during the second quarter, Holdings Channel reports. The institutional investor owned 54,100 shares of the company’s stock after buying an additional 1,400 shares during the period. Swiss National Bank owned 0.11% of Accelerate Diagnostics worth $778,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Metropolitan Life Insurance Co. NY raised its position in Accelerate Diagnostics by 2.6% in the first quarter. Metropolitan Life Insurance Co. NY now owns 17,271 shares of the company’s stock worth $248,000 after buying an additional 437 shares in the last quarter. Royal Bank of Canada raised its position in Accelerate Diagnostics by 12.0% in the first quarter. Royal Bank of Canada now owns 17,485 shares of the company’s stock worth $251,000 after buying an additional 1,870 shares in the last quarter. Fairfield Bush & CO. raised its position in Accelerate Diagnostics by 3.3% in the first quarter. Fairfield Bush & CO. now owns 18,875 shares of the company’s stock worth $271,000 after buying an additional 600 shares in the last quarter. Chartist Inc. CA bought a new position in Accelerate Diagnostics during the second quarter worth approximately $899,000. Finally, Renaissance Technologies LLC bought a new position in Accelerate Diagnostics during the first quarter worth approximately $1,019,000. Institutional investors and hedge funds own 35.62% of the company’s stock.
Accelerate Diagnostics Inc. (NASDAQ:AXDX) traded down 1.57% on Friday, reaching $26.95. 265,229 shares of the company’s stock traded hands. The firm’s market capitalization is $1.38 billion. The firm’s 50 day moving average price is $25.06 and its 200 day moving average price is $17.87. Accelerate Diagnostics Inc. has a 52-week low of $10.29 and a 52-week high of $28.50.
A number of research analysts recently commented on AXDX shares. BTIG Research reiterated a “buy” rating and set a $26.00 price objective on shares of Accelerate Diagnostics in a research note on Wednesday, June 15th. Zacks Investment Research upgraded shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research note on Monday, September 19th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Accelerate Diagnostics from $17.00 to $25.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 9th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $25.33.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.
Want to see what other hedge funds are holding AXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accelerate Diagnostics Inc. (NASDAQ:AXDX).
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.